文献速递头颈介入甲状腺与浅表US

甲状旁腺功能亢进患者射频消融的安全性:10年真实世界多中心经验

Safety of radiofrequency ablation in patients with hyperparathyroidism: a 10-year real-world multicenter experience.
PubMed 文献 · Eur Radiol · 2025-05-23

该回顾性多中心研究分析了2013年1月至2024年4月接受超声引导下射频消融治疗的320例甲状旁腺功能亢进患者,总体并发症发生率为22.2%(71/320),其中主要并发症9.4%(30/320)、次要并发症14.7%(47/320)。继发性甲状旁腺功能亢进是总体并发症(OR 2.132,P=0.014)和次要并发症(OR 2.077,P=0.046)的危险因素,最大直径是主要并发症的唯一危险因素(OR 1.508,P=0.047)。

要点

  • 总体并发症发生率22.2%(71/320),主要并发症9.4%(30/320),次要并发症14.7%(47/320)。
  • 继发性甲状旁腺功能亢进患者并发症发生率26.6%(54/203),高于原发性患者的14.5%(17/117)。
  • 继发性甲状旁腺功能亢进是总体并发症(OR 2.132,P=0.014)和次要并发症(OR 2.077,P=0.046)的危险因素。

核心结论

  • 射频消融是耐受性良好的技术,用于甲状旁腺功能亢进时主要并发症发生率可接受地低;加强继发性甲状旁腺功能亢进及大体积增生腺体患者的管理策略可能有助于减少并发症。

研究设计与样本

  • 回顾性研究,纳入2013年1月至2024年4月接受超声引导下经皮射频消融治疗的甲状旁腺功能亢进患者320例,其中原发性甲状旁腺功能亢进117例、继发性甲状旁腺功能亢进203例;采用逻辑回归分析评估影响因素。

诊断标准与关键数值

  • 总体并发症发生率22.2%(71/320),主要并发症9.4%(30/320),次要并发症14.7%(47/320),6例同时发生主要和次要并发症。
  • 继发性甲状旁腺功能亢进患者中54例(26.6%,54/203)发生并发症,包括22例主要和36例次要并发症;原发性甲状旁腺功能亢进患者中17例(14.5%,17/117)发生并发症,包括8例主要和11例次要并发症。
  • 继发性甲状旁腺功能亢进为总体并发症的危险因素(OR 2.132,P=0.014)及次要并发症的危险因素(OR 2.077,P=0.046)。
  • 最大直径为主要并发症的唯一危险因素(OR 1.508,P=0.047)。

临床应用与阅片要点

  • 对于继发性甲状旁腺功能亢进患者及增生腺体体积较大的患者,作者认为加强管理策略可能有助于减少并发症。
  • 射频消融可作为需要干预的原发性和继发性甲状旁腺功能亢进患者的非手术替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: US-guided percutaneous radiofrequency ablation (RFA) is a validated procedure for hyperparathyroidism (HPT). However, it is associated with potentially significant complications, and data regarding the incidence and risk factors associated with RFA-related complications are limited.

OBJECTIVE: To assess the complication rates associated with RFA for HPT and identify the potential influential factors.

METHODS: This retrospective study was to investigate the associated complications in HPT patients who underwent RFA between January 2013 and April 2024. We collected and analyzed complications for these patients, focusing on their categories and rates. Logistic regression analysis was used to assess the crucial factors.

RESULTS: Three hundred twenty patients were included, including 117 cases of primary hyperparathyroidism (pHPT) and 203 cases of secondary hyperparathyroidism (sHPT). The overall complication rate was 22.2% (71/320), with 9.4% (30/320) being major complications and 14.7% (47/320) minor complications. Six patients experienced both major and minor complications. Among sHPT patients, 54 cases (26.6%, 54/203) experienced complications, including 22 major cases and 36 minor cases; however, among pHPT patients, 17 cases experienced complications (14.5%, 17/117), with 8 being major and 11 being minor. sHPT was identified as a risk factor for overall complications (odds ratio, 2.132; p = 0.014) and minor complications (odds ratio, 2.077; p = 0.046). Maximum diameter was the only risk factor for major complications (odds ratio, 1.508, p = 0.047).

CONCLUSIONS: RFA is a well-tolerated technique with an acceptably low incidence of major complications for HPT. Enhanced management strategies involving patients with sHPT and large hyperplastic glands may help mitigate complications.

KEY POINTS: Question Is ultrasound-guided RFA a safe nonsurgical alternative to traditional parathyroidectomy for patients with pHPT and sHPT who require intervention? Findings Ultrasound-guided RFA is a safe procedure for treating HPT. However, patients with sHPT and large hyperplastic glands are more likely to develop complications. Clinical relevance RFA is a well-accepted technique with a relatively low complication rate and can be used as a non-surgical alternative in the management of HPT.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jiang T, Chai H, Shan X, et al. Safety of radiofrequency ablation in patients with hyperparathyroidism: a 10-year real-world multicenter experience. Eur Radiol. 2025. PMID: 40410329. doi:10.1007/s00330-025-11688-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。